Skip to content
Study details
Enrolling now

Olanzapine for Cancer Appetite Loss

OHSU Knight Cancer Institute
NCT IDNCT05705492ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

66

Study length

about 1.5 years

Ages

18+

Locations

1 site in OR

What this study is about

This trial is testing if olanzapine helps manage appetite loss in people with advanced cancers like esophageal, lung, or colon cancer. Olanzapine is a medication that may stimulate appetite and improve quality of life.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Questionnaire Administration
  • 2.Take Olanzapine
  • 3.Take Placebo Administration

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

olanzapine

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Change in Weight, Incidence of adverse events, Patient Reported Quality of Life, Patient Reported Symptoms, Physical Function, Proportion of patients with ≥1 unplanned hospitalization

Body systems

Oncology